MedTrace Logo

A Controlled Study to Evaluate the Efficacy and the Tolerability of a Cosmetic Active Ingredient Intended for Subjects With Atopic Dermatitis

NCT05057351 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2021-09-27

No results posted yet for this study

Summary

Evaluation of safety and clinical efficacy of an active ingredient versus placebo for the treatment of mild to moderate Atopic Dermatitis (AD) adults.

Conditions

  • Mild to Moderate Atopic Dermatitis

Interventions

OTHER

Isopentenyltheophylline 0.44% + Glycerin 4.56%

Application of topical cream twice a day on the area affected by Atopic Dermatitis

OTHER

Glycerin 4.56%

Application of topical cream twice a day on the area affected by Atopic Dermatitis

Sponsors & Collaborators

  • Complife Italia S.r.l

    collaborator UNKNOWN

  • Greenpharma S.A.S.

    lead OTHER

Principal Investigators

  • Gloria Roveda, MD · Complife Italia S.r.l

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2020-11-30
Completion
2021-03-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05057351 on ClinicalTrials.gov